Quantcast

Latest Trovagene Inc. Stories

2014-09-17 08:29:43

SAN DIEGO, Sept. 17, 2014 /PRNewswire/ -- Trovagene, Inc., (NASDAQ: TROV) a developer of cell-free molecular diagnostics, announced today that Alberto Bardelli, Ph.D., has joined the Company's Scientific Advisory Board. Dr. Bardelli was among the first to identify mutations in the kinase genes that are associated with colorectal cancer and other malignancies. Currently, he is at the Department of Oncology, Torino Medical School, Institute for Cancer Research in Candiolo, Italy....

2014-08-26 08:31:16

Data from Urinary Cell-free DNA Presented at Next Generation Dx Summit WASHINGTON, Aug. 26, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV) presented data at the Next Generation Dx Summit; Moving Assays to the Clinic with an oral presentation entitled "Targeted Detection and Monitoring of Cell Free Tumor DNA in Urine." In this presentation Trovagene reported the analytical component of its Precision Cancer Monitoring (PCM) platform and results from several studies demonstrating...

2014-08-25 08:27:55

SEATTLE, Aug. 25, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that results from two independent clinical studies were presented at the 29th International Papillomavirus (IPV) Conference. Results from both pilot studies consistently demonstrated that the Company's urine-based assay for the detection of high-risk HPV had high sensitivity (greater than 90%) for identifying women with high grade cervical...

2014-08-20 08:27:55

SAN DIEGO, Aug. 20, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that results from two clinical studies will be presented at the 29th International Papillomavirus (IPV) conference for the Company's urine-based diagnostic test for the detection of high risk strains of Human Papillomavirus (HPV). The IPV conference is scheduled to take place in Seattle from August 21(st) to 25(th). Additionally, a new U.S. patent...

2014-08-12 08:30:30

SAN DIEGO, Aug. 12, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that K. Peter Hirth, Ph.D., has joined the Company's Scientific Advisory Board. Dr. Hirth is an industry leader and innovator with over 30 years of biotechnology and pharmaceutical discovery and development experience. A pioneer in the field of personalized medicine, Dr. Hirth led the organizations that developed both Sutent(®) and Zelboraf(®);...

2014-08-07 16:28:49

SAN DIEGO, Aug. 7, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today reported its financial results for the three months and six months ended June 30, 2014. http://photos.prnewswire.com/prnvar/20120620/LA28014LOGO "Trovagene is continuing to demonstrate the benefits of our precision cancer monitoring platform and is progressing toward our commercial roll-out later this year," said Antonius Schuh, Ph.D., chief executive officer of...

2014-07-30 08:33:16

SAN DIEGO, July 30, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that it will report financial results for the second quarter and the six months ended June 30, 2014 on Thursday, August 7, 2014 at 4:00 p.m. Eastern Daylight Time (1:00 p.m. Pacific Daylight Time). http://photos.prnewswire.com/prnvar/20120620/LA28014LOGO Trovagene's management team will host a conference call on Thursday, August 7, 2014 at 5:00...

2014-07-01 08:29:52

Strengthens balance sheet to fund clinical programs, commercialization efforts, and continued expansion of oncogene mutation portfolio for cancer monitoring SAN DIEGO, July 1, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV) today announced that it has secured an unrestricted debt facility in the amount of $15 million from Silicon Valley Bank and Oxford Finance LLC. The additional capital will be used to support ongoing development and commercialization activities for the...

2014-06-30 08:30:41

SAN DIEGO and CHICAGO, June 30, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), the Robert H. Lurie Comprehensive Cancer Center of Northwestern University (Lurie Cancer Center) and the Northwestern Medicine Developmental Therapeutics Institute (NMDTI) have entered into a strategic partnership to conduct a translational research program designed to assess the utility of Trovagene's urine-based cell-free oncogene mutation monitoring technology in clinical practice....

2014-06-16 08:28:29

Company continues to engage leading cancer treatment centers to investigate non-invasive methods of cancer mutation detection in order to advance patient care SAN DIEGO, June 16, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV) today announced that it has entered into a clinical collaboration with Dana-Farber Cancer Institute to investigate the utility of quantitative urine-based mutation detection and the ability to monitor tumor mutation burden and treatment response over time...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'